An important issue in toxicology is the suitability of the data obtained with experimental animals for human risk assessment. Because it is not possible to use humans in long-term toxicological studies, the use of animals will continue. However, the data obtained in animal studies can be better extrapolated to the patient by utilizing bridging studies with in vitro models of human drug metabolism. There are 2 basic categories of in vitro methods for the examination of human liver drug metabolism. The first group of in vitro methods consists of the cellular models, which include primary hepatocytes, liver slices, and cell lines. The second group is the use of preparations of the drug-metabolizing enzymes such as tissue homogenates, subcellular fractions, and isolated enzymes. Studies modeling both the human and experimental animal metabolism of a drug are useful in the design of toxicological studies. In vitro studies can identify metabolites, species-specific metabolic routes, and the experimental animal model that best reflects the potential human exposure to the drug and its metabolites. This information can also be useful in the design of the clinical studies by identifying human metabolites, the enzymes responsible for the metabolic clearance of the drug, the effects of genetics and other host factors on the metabolism of the drug, and potential drug-drug interactions. An example of how such information is generated and interpreted is presented.
INTRODUCTION
During the development of a drug, toxicology and drug metabolism studies are performed using various in vivo animal models to demonstrate the safety of the potential drug in order to support clinical trials (4, 18) . A critical concern regarding these toxicology and drug metabolism studies is whether or not the exposure of an animal to the parent compound and its metabolites truly reflects the situation in the patient (4) . In vitro drug metabolism studies utilizing models of human drug metabolism can be performed to bridge this information gap (33) . Through the use of in vitro comparative studies, using tissues or enzymes from humans and experimental species, it is possible to better extrapolate the risk assessment information obtained in the toxicology studies to the patient.
As a result of the ever increasing regulation of the pharmaceutical industry, the process of developing a drug is increasing in cost and time. Studies using human tissue or enzymes in vitro can be utilized in a cost-efI'ective and timely manner to target or guide the clinical studies. For example, in vitro studies can examine potential drug-drug interactions and the effect of environmental agents, ethnic background, gender, and genetics on the metabolism of a drug candidate (26, 33) . How such information is generated and interpreted is the subject of this manuscript.
IN VITRO METHODS
In broad terms, the in vitro methods available to study human hepatic drug metabolism can be divided into 2 categories. The first broad category is composed of cellular systems. Included in this group are primary hepatocytes in suspension or monolayer culture (6, 16) , liver slice culture (2) . and hepatocyte derived cell lines (9) . The second category is composed of preparations of the drug-metabolizing enzymes. Included in this group are the use of subcellular fractions, such as microsomal and cytosolic fractions (33) . and the use of isolated enzyme preparations that can be obtained by purification tech-,.&dquo; -......-~&dquo;&dquo;&dquo;'...-,......---------niques or more easily through heterologous complementary DNA (cDNA) expression systems (12, 15. 20. 33) . Each of these in vitro model systems have advantages and disadvantages, which are outlined later.
The information obtained using in vitro models of human drug metabolism is useful to both the toxicologist and the clinician. The toxicologist and drug metabolism scientist can use these systems for several purposes. First, these systems can be used to generate metabolites of a new drug candidate for metabolite identification and analytical assay development. The in vitro systems can be used to compare the profile of metabolites formed by the different species, which may be useful in explaining species-specific toxic or pharmacologic effects of a drug. The effect of the drug directly on the hepatocyte can be examined with the cellular systems.
Finally, the information obtained with the in vitro systems can aid in the rational and justifiable species selection for toxicological testing. The information obtained from in vitro studies can also be used to support the clinical development of a drug candidate. Specifically, the in vitro systems can be used to identify human metabolites of a drug candidate, which then can be compared to those predicted by the studies with the experimental species, thus assuring that the animals were exposed not only to the parent compound but also to the major human metabolites. Furthermore, the human enzyme(s) responsible for the metabolic clearance of the drug candidate can be determined. By knowing the factors that affect the activity of this enzyme such as genetic polymorphisms, induction, inhibition, and disease states, it is possible to target or guide the clinical program to those studies that would enhance the information about the pharmacokinetics of the drug and eliminate those studies that are not scientifically valid. The cost-to-benefit ratio of such in vitro studies is great.
Cellular Systems
The various cellular systems include primary hepatocytes, liver slices, and cell lines (2, 6, 9, 16) . Primary hepatocytes isolated by collagenase perfusion have the major advantage over the various systems using enzyme preparations in that in the hepatocyte all the potential metabolic pathways are intact and available to metabolize the compound of interest. Furthermore, nuclei and mitochondria are present in these cells and are known to contain enzymes that occasionally participate in the metabolism of drugs. The hepatocytes can be used in suspension culture for metabolism studies or monolayer culture primarily for induction studies. There are several disadvantages of the isolated hepatocyte model, the first of which is that they are not readily cryopreserved (6) . Although cryopreservation techniques are improving, currently only about 60% of the hepatocytes survive thawing and culturing, which suggests that a select population of cells remains. Another disadvantage is that the expression of the various drug-metabolizing enzymes is altered upon isolation and culturing (6, 16) . This effect is minimized by using short-term suspension cultures. However, with monolayer cultures, up to 75% of the total cytochrome P-450 is lost as early as 24 hr after preparation of the hepatocytes. Although monolayer cultures may not be useful for metabolism studies because of this loss of drug-metabolizing enzymes, they are very useful for examining the ability of a drug candidate to induce the human drug-metabolizing enzymes (7) .
Liver slices have all the advantages of the primary hepatocytes in suspension culture (2) . Furthermore, the complete architecture of the liver is maintained with the slice. Thus, unlike the primary cultures of hepatocytes, which contain only parenchymal cells, all the different cell types found in the liver are represented and available to metabolize a test substance in the slice model. The major problems associated with the liver slice is that they currently cannot be stored for long periods of time and little work has been done to validate their use in induction studies.
Transformed human cell lines have also been used as a model of human drug metabolism (9) . However, all the cell lines examined to date do not accurately reflect the metabolic potential of their parent cell. Therefore, cell lines appear to be of limited use in drug metabolism studies.
Enzyme Preparations
Preparations of drug-metabolizing enzyme systems include the use of subcellular fractions and isolated drug-metabolizing enzymes. By far the most often used in vitro system for drug metabolism studies has been the use of various subcellular fractions (33) , which include whole-cell homogenates: cell homogenates from which the cellular debris, nuclei, and mitochondria have been removed termed the S-9 fraction; microsomes, which are closed vesicles of endoplasmic reticulum; and cytosol. These subcellular systems are easy to prepare and can be made from very small amounts of tissue and, of these, the microsomal fraction has been shown to retain enzymatic activity when stored under appropriate conditions. The levels of the various drug-metabolizing enzymes in the subcellular fractions can readily be determined, allowing the investigator to characterize the metabolic potential of these systems with respect to standard markers of the catalytic activity of the drug-metabolizing enzymes (33) . These systems are easily manipulated, and by knowing the source of the tissue it is possible to study the effect of factors such as genetics and disease state on the metabolism of a drug candidate. The enzyme(s) responsible for the metabolic clearance of a drug can be determined through the use of subcellular systems. The disadvantage of the subcellular systems is that all the cofactors required for the drug-metabolizing enzymes must be added to the incubation. Furthermore, some enzymes that may work in a sequential fashion (e.g., oxidation followed by conjugation with glutathione) are located in different subcellular fractions. Thus, sequential metabolism of a compound is difficult to examine with these systems.
Isolated enzyme preparations are available from 2 sources: purification from an appropriate tissue or cDNA-directed expression systems (12, 15, 33) . In this type of study, the metabolism of a drug by a single enzyme is usually examined. If the enzyme being examined is found to metabolize a drug, it is possible to implicate that enzyme in the metabolic clearance of the drug. The purification of each human drug-metabolizing enzyme is not practical or possible. However, cDNA-directed expression systems are now available for the major enzymes involved in human drug metabolism. The major advantage to the cDNA-directed expression systems is that they do not require human tissue yet yield a continuous supply of drug-metabolizing enzymes. A major disadvantage of these systems is that they are the most artificial of all systems described here, in that often the isolated enzyme must be reconstituted with other enzymes, lipids, and/or cofactors to achieve optimum catalytic activity. Also, the expressed enzymes currently available have relatively low turnover numbers, which can make them difficult to use with poor substrates. Finally, it is not currently possible to express more than a few enzymes at the same time, making sequential or concurrent metabolism difficult to study.
Over the past 10 yr, thanks to the availability of human liver samples and to molecular biological techniques, a great deal has been learned about the catalytic activities and regulation of expression of the enzymes involved in drug metabolism (33) . Metabolism of a drug is often required before the drug can be readily eliminated from the body. The large interindividual differences observed in the effects of drugs is at least in part determined by the variation of the expression and catalytic activity of the drugmetabolizing enzymes. There are 4 general sources of the interindividual variation in the catalytic activity of the drug-metabolizing enzymes. First is the influence of genetics on the expression of the en-zymes (13) . Genetic polymorphisms have been well characterized for ? different cytochromes P-450 (P-450), those responsible for debrisoquine sparteine metabolism and (,S')-mephens-toin 4 -hydroxylation and for the N-acetyltransferase. Ethnic background (34) and gender (1) also influence the metabolism of certain drugs. The second source of interindiv idual differences in the catalytic activity of the drugmetabolizing enzymes is that many of them can be induced by treatment of the patient with the drug or other xenobiotics (31, 33) . Inhibition by competing substrates and inactivation by reactive substrates is the third source of interindividual differences in drug metabolism (26, 33) . Finally, host factors such as disease states is the fourth source of interindividual differences in the activity of the drugmetabolizing enzymes (23) . These interindividual differences in the level of expression and catalytic activity of the various drug-metabolizing enzymes can result in an increase or decrease in pharmacological response to a drug or a toxic response due to unusual levels of a drug or metabolite. However, by determining the enzyme(s) responsible for the metabolic clearance of a drug candidate and by knowing the factors that alter the catalytic activity of that enzyme, it is possible to predict interindividual differences in the metabolism of the drug, thus aiding in the rational development of the drug. The following is a brief overview of the major hepatic enzymes involved in human drug metabolism.
The Drug-Metabolizing Enzymes
The Cytochromes P-450: The P-450s are a superfamily of heme-thiolate proteins that are the oxidases of the monooxygenase system. The nomenclature system devised for the P-450s is based on their evolutionary relationships (25) . In this nomenclature system, the deduced amino acid sequences of all of the P-450 genes are compared, and those P-450s that share at least 40% identity are defined as a family (designated by CYP followed by a roman or arabic numeral, e.g., CYP3). The families are further divided into subfamilies (designated by a capital letter, e.g., CYP3A), which are comprised of those forms that are at least 55% related by their deduced amino acid sequences. Finally, individual P-450s are assigned an arabic numeral (e.g., CYP3A5). The members of 3 P-450 families (CYP 1. CYP2, and CYP3) appear to be responsible for metabolizing the vast majority of drugs. In the human liver, at least 15 P-450s have been characterized to varying degrees. It is important to note that at concentrations of the substrates found under physiologic conditions, enzyme kinetics often dictate that a single P-450 is the primary catalyst of the metabolism. Therefore, the rate and pathway of the metabolic clearance of a compound is determined by the phenotype of an individual with respect to the forms and amounts of the individual P-450s expressed by the individual. Finally, it has become apparent that the catalytic activities and the regulation of the expression of the human P-450s are often quite different than those found for the related forms in the experimental animals. Following is a brief discussion on the human P-450s involved in drug metabolism. For a more detailed discussion, see Cholerton et al (5) , Gonzalez (12) (33) .
The human CYP family contains 2 forms of P-450, CYP1A1 and CYP 1 A2 (Table I) . CYP 1 A l, also referred to as the aryl hydrocarbon hydroxylase, is orthologous to the CYP 1 A 1 forms observed in experimental species. However, human CYP 1 A 1 does not appear to be expressed in human liver. Human CYPIAL has been detected in extrahepatic tissue, most notably the lung (29) and placenta where it appears to be inducible by polycyclic aromatic hydrocarbons (Table I) .
Human CYP1A2 (Table I) is a hepatic P-450 that does not appear to be expressed in extrahepatic tissues. The levels of human CYP 1 A2 vary greatly among hepatic microsome samples ( 100-fold), with this variation being attributed to the exposure of some individuals to inducers of CYP 1 A2 such as cigarette smoke (Table I) . Caffeine demethylation, ethoxyresorufin O-deethylation, and phenacetin O-deethylation are marker in vitro catalytic activities for CYP1A2 with 7,8-benzoflavone and furafylline demonstrated to be inhibitors of CYP 1 A2.
The largest family of P-450s is the CYP2 family (Table II ). The first human P-450 in this family is CYP2A6, and it has only recently been identified (31, 33) . Coumarin 7-hydroxylation is the formselective catalytic activity of CYP2A6. This activity has been shown to vary greatly between human liver specimens (up to 170-fold). This may be the result of the induction of CYP2A6, because barbiturates and dexamethasone induce the level of CYP2A6 by about 3-fold in cultures of primary human hepatocytes.
There has been extensive examination of the CYP2B subfamily in the experimental species because it contains the major forms of P-450 induced by barbiturates. A human gene encoding a related P-450, CYP2B6, has been identified. However, recent work (24) has demonstrated that CYP2B6 is only expressed in about 30% of the livers examined, and then only in very low levels. Furthermore, the level of expression of human CYP2B6 did not appear to be influenced by barbiturate treatment. Therefore, the importance of CYP2B6 in human hepatic drug metabolism is unknown. The human CYP2C subfamily is composed of 5-6 P-450s (Table II ). The first member of the human CYP2C subfamily is CYP2C8. The immunochemical levels of CYP2C8 in banks of human liver mi- crosomes have been shown to vary by as much as 20-fold. The levels of CYP2C8 appear to be bimodally distributed with a third of the human liver specimens examined containing higher levels of CYP2C8 than the remaining two-thirds of the samples. A form-selective catalytic activity for CYP2C8 has not yet been identified; however, retinoic acid and tolbutamide appear to be low-affinity substrates of CYP2C8.
The next 2 forms, CYP2C9 and CYP2C 10 (Table  II) , differ only by 2 amino acids and are believed to be allelic variants of the same gene (25) . The marker catalytic activities for CYP2C9/ 10 are phenytoin hydroxylation, tolbutamide hydroxylation, and (S)warfarin 7-hydroxylation, with these activities varying about 20-fold in banks of human liver microsomes. Sulfaphenazole has been shown to be a relatively selective inhibitor of 2C9/10. Rifampicin treatment has been shown to increase tolbutamide hydroxylation, indicating that 1 or more of these forms may be inducible.
A gene encoding human CYP2C 18 has been identified through recombinant DNA methodology (28). The role of CYP2C 18 in drug metabolism is currently not known, although cDNA-directed expression systems have shown the gene to code for a catalytically active P-450 (11) . The 4 '-hydroxylation of (S)-mephenytoin is catalyzed by CYP2C19 (32) (Table II) and is of interest because clinical studies have demonstrated a genetic polymorphism in the ability of individuals to 4'hydroxylate (,S~-mephenytoin. The poor metabolizer phenotype has been shown to be inherited as an autosomal recessive trait with poor metabolizers comprising approximately 5% of the Caucasian population and 20% of the Asian population. The activity of the (,S~-mephenytoin 4'-hydroxylase has been shown to vary by more than 150-fold in a bank of human liver specimens. Interestingly, rifampicin administration to extensive metabolizers of (S')-mephenytoin has been shown to increase S-mephenytoin 4'-hydroxylation.
CYP2D6 is responsible for the genetic polymorphism in debrisoquine/sparteine metabolism. The poor debrisoquine/sparteine metabolizer phenotype is inherited as an autosomal recessive trait with the poor metabolizer phenotype comprising about 8% of the Caucasian population and approximately 1 % of the Asian and African-American populations. It is important to note that both the CYP2D6 and CYP2C 19 genetic polymorphisms demonstrate ethnic differences in their mode of inheritance. More than 30 therapeutically useful drugs are metabolized by CYP2D6. Debrisoquine 4-hydroxylation. sparteine oxidation, dextromethorphan 0-demethylation, and bufuralol 1'-hydroxylation are all used as in rilro assays for CYP2D6 activity, with these activities varying in human liver microsomes by 25- fold. Quinidine is a highly effective inhibitor of CYP2D6-mediated metabolism and has been used in vivo to convert rapid metabolizers to phenotypically poor metabolizers. Human CYP2E 1 is toxicologically important in that it converts many small organic compounds (i.e., carbon tetrachloride, N-nitrosodimethylamine, acetaminophen, and ethanol) to reactive intermediates. Chlorzoxazone 6-hydroxylation is used in vivo and in vitro and N-demethylate N-nitrosodimethylamine is used in vitro as probes for CYP2E 1 catalytic activity (Table II) . CYP2E 1 is inhibited by disulfuram. The levels of human 2E 1 have been shown to vary in microsome samples by up to 50fold. This variation in activity may be the result of the induction of human CYP2E 1 by ethanol or isoniazid or the result of a polymorphism found in the part of the CYP2E 1 gene that regulates its expression (19) .
The CYP3 family of cytochromes P-450 is thought to be the dominant family in human drug metabolism. Four P-450s comprise the human CYP3A subfamily (Table III) . These forms are responsible for the metabolism of a large number of structurally diverse xenobiotics and endobiotics. The first 2 CYP3A subfamily members are CYP3A3 and CYP3A4. The majority of studies performed to date have not been able to distinguish their individual contributions to drug metabolism; thus, they are often referred to as CYP3A3/4. Erythromycin N-demethylation, cyclosporin metabolism, nifedipine oxidation, midazolam hydroxylation, testosterone 6{3-hydroxylation, and cortisol 60-hydroxylation are probes of CYP3A3/4 catalytic activity. The levels of CYP3A3/4 vary by as much as 60-fold among human liver microsomal samples. The various markers associated with CYP3A3/4 are elevated in liver samples obtained from individuals receiving troleandomycin, rifampicin, barbiturates, glucocorticoids, and phenytoin. Inhibitors of CYP3A include troleandomycin, gestodene, and flavones found in grapefruit such as quercetin. A gender difference has been observed using in vivo probes of CYP3A, which indicates that women may metabolize CYP3A substrates faster than men (30) .
The remaining 2 members of the human CYP3A subfamily are CYP3A5 and CYP3A7 (Table III) . and their roles in drug metabolism have not been as extensively studied as that of C~'P3A3,'4. CYP3A5 is polvmorphically expressed, having been detected in only about 20-25% of the examined microsomal samples from adults. In comparison to CYP3A3/4. CYP3A5 appears to metabolize fewer substrates and at a generally slower rate. CYP3A7 (17) . Multiple forms of human FMOs have recently been described (17) . Human fetal FMO termed FMO I is not significantly expressed in the adult liver. A second human form, FM03, has been cloned and found to be the major form in adult human liver. The formation of trans-(S~-nicotine N-1'-oxide has been attributed to FM03 and appears to be a form-selective catalytic probe (33) . Methimazole is a competitive inhibitor of the FMOs. The FMOs are not believed to play a significant role in the metabolic clearance of many drugs. Phase II Enzymes: The Phase II enzymes conjugate small endogenous molecules like glucuronic acid, amino acids, and sulfuric acid onto polar functional groups often introduced onto the xenobiotic by the Phase I oxidative enzymes. Glucuronidation of phenols, alcohols, tertiary amines, and other groups by microsomal uridine diphosphate-glucuronosyltransferases (UDPGT) is often a major route of elimination of a drug. The Phenotyped Human Liver Microsomes. As indicated previously, for many of the P-450s and a few of the other enzymes involved in drug metabolism, form-selective catalytic activities have been identified. In addition, antibodies that can be used to immunoquantify the levels of many of the drugmetabolizing enzymes have been characterized. Therefore, it is possible to use these antibodies and form-selective assays to phenotype a bank of human liver samples with respect to the relative levels of the drug-metabolizing enzymes found in the liver samples. An example of a phenotyped bank of human liver microsomes has recently been published (33) . This bank of 14 human liver microsomes has been phenotyped with respect to the levels of all the P-450s identified in the human liver, except CYP2B6, by a combination of immunoquantification and/or form-selective catalytic activities. The levels of FM03 have also been determined by immunoquantification and catalytic activity. In addition, general assays of glucuronidation, sulfation, acetylation, methylation, and glutathione conjugation were performed with this bank of 14 human liver samples. This unique resource can be used to determine the enzyme responsible for the metabolic clearance of a compound, to predict the interindividual variation in the metabolism of a drug, for in vitro drug-drug interaction studies, and with subcellular fractions from the experimental species, to determine interspecies variation in the metabolism of a drug. An example of how such studies are performed and interpreted follows.
IN VITRO METABOLISM OF ZATOSETRON
Zatosetron is a 5-HTg receptor antagonist being developed for its potential anti-anxiety activity in humans. After a single oral dose of zatosetron to male volunteers, 60% of the dose was isolated as metabolites (10) . The major route of metabolism in these clinical studies was found to be a stereospecific N-oxidation of zatosetron to 8-a-methyl, 8-#-oxo zatosetron (zatosetron N-oxide). N-desmethyl zatosetron (NdM zatosetron), and 3-hydroxy zatosetron (30H zatosetron) were found to be minor metabolites. This metabolite profile differs from the in vivo metabolite profile observed in rat, dog, and mouse. In these species, extensive metabolism resulted in primarily 30H zatosetron formation. NdM, 3-keto, and N-desmethyl, 3-hydroxy zatosetron were also detected in these animals. An equally important observation was that only a small amount zatosetron N-oxide was formed by these animals.
To further investigate the species difference in zatosetron metabolism, the kinetics of metabolite formation was examined in vitro with hepatic microsomes obtained from rat, monkey, and human samples (27) . Table IV indicates the metabolites detected following incubation of zatosetron with rat, monkey, and human hepatic microsomes. The apparent enzyme kinetics parameters of I~m and V max were determined assuming the involvement of a single catalytic site by nonlinear regression analysis. The ratio of V max to K_, or intrinsic clearance value, was calculated to examine the relative ability of the microsomal enzymes to metabolize zatosetron to its various metabolites. The higher the ratio, the more efficient the enzyme is in forming that metabolite.
In the incubations with rat microsomes, 30H zatosetron, with an intrinsic clearance value of 5.2, was formed with the highest efficiency. This agrees with the in vivo data. The intrinsic clearance values for zatosetron N-oxide and NdM zatosetron formation were also relatively high (Table IV) , indicating that zatosetron is extensively metabolized by the rat microsomes. These in vitro findings agree well with the in vivo rat data. Two different human microsomal samples were used to determine the in vitro kinetics of zatosetron metabolism. The human samples were HL-E, a sample with high levels of CYP3A and CYP2A6, and HL-J, a sample with &dquo;normal&dquo; drug-metabolizing enzyme activity. In both of these human samples, the intrinsic clearance value for zatosetron N-oxide formation was found to be much greater (at least 10-fold) than that for the formation of NdM zatosetron and 30H zatosetron. Again, there is an excellent in vitro-in vivo relationship indicating that zatosetron N-oxide is the major metabolite in both situations and little else was formed.
The kinetics of the formation of metabolites of zatosetron by rhesus monkey microsomes, a species not tested in vivo, was also examined. The highest intrinsic clearance value was obtained for the formation of zatosetron N-oxide. Relatively high in- (27) .
trinsic clearance values were also seen for the formation of 30H zatosetron, NdM zatosetron, and the second N-oxide stereoisomer of zatosetron. Therefore, the in vitro data suggest that zatosetron N-oxide would be the major metabolite formed in vivo by the rhesus monkey, which is similar to what was observed with human volunteers. However, unlike the human but similar to the other species examined, the overall metabolism of zatosetron in the monkey would be predicted to be extensive.
These results indicate that as an animal model for human in vivo exposure to zatosetron and its metabolites, rhesus monkey may be a better choice than rat, mouse, or dog. It also is apparent that the rhesus monkey is not ideal because the intrinsic clearance values for the secondary metabolites in the rhesus monkey indicate that the overall metabolism of zatosetron would be more rapid and extensive than that found in the human volunteers.
The in vitro examination of the metabolism of a drug can also be used to address clinical concerns about drug candidates such as their potential for drug~rug interactions and the potential for differences in metabolism in human populations due to interindividual differences in enzyme levels (26. 33) .
To address these concerns with zatosetron. it was necessary to identify the P-450(s) responsible for zatosetron metabolism to its primary metabolite of zatosetron N-oxide. The analyses of the enzyme kinetics of zatosetron (27, 33) . b The levels of CYP3A were determined by immunoblot analyses as previously described (33) and are expressed as a percentage of the level obtained for human liver A. N-oxide formation demonstrated that zatosetron binds with relatively low affinity (K~ &horbar;250 ~cln) to the active site of a single human enzyme. To identify the enzyme responsible for zatosetron N-oxide formation, the rate of its formation was determined using a bank of 14 human liver microsomal samples. This bank of human microsomal samples had previously been phenotyped with respect to the relative levels of the P-450s and FMOs. The ability of the microsomal samples to produce zatosetron N-oxide was found to vary 17. f -fold (Table V) . The ability of these microsomal samples to form zatosetron N-oxide was then correlated to the relative levels of the phenotyped P-450s and FM03 (33) . The only significant correlations obtained (Table V) To further investigate the role of CYP3A in the formation of zatosetron N-oxide, the effect of compounds known to inhibit CYP3A on zatosetron N-oxide formation was examined. Therefore, the effect of quercetin, an uncompetitive inhibitor of CYP3A, and midazolam, a high-affinity (K_ = 10 >M) CYP3A substrate, on zatosetron N-oxide formation by human liver microsomal samples was determined. Quercetin was found to be a high-affinity (K, == 13.6 ~M), uncompetitive inhibitor of zatosetron N-oxide formation. Midazolam was found to be a competitive inhibitor of zatosetron N-oxide formation with a K, of 45.1 1 um. The results of the inhibitor studies along with the correlation of zatosetron N-oxide formation rates with human microsomal levels of CYP3A indicate that CYP3A is responsible for the formation of the major human metabolite produced from zatosetron.
The results of the inhibition studies are also useful in predicting potential drug-drug interactions. The parameter useful in such predictions is the ratio of the affinity of the inhibitor (K;) to the affinity of the substrate (Km) for the enzyme responsible for the metabolism. In the case of quercetin inhibition of zatosetron N-oxide formation, a Ki-to-Km ratio of 0.05 indicates that quercetin will likely inhibit the formation of zatosetron N-oxide because quercetin has a much greater affinity for CYP3A than zatosetron. A similar statement can be made for midazolam because in this case the K;-to-K~, ratio is about 0.2. On the other hand, zatosetron was found to be a low-affinity inhibitor (K; = 288 ~M) of CYP3A-mediated 1'-hydroxy midazolam formation (K~ = 10 Am). Because the Ki-to-K_ ratio for the inhibition of midazolam metabolism by zatosetron is about 30, there is little chance zatosetron would effectively compete with midazolam for binding the active site of CYP3A.
The information obtained in the in vitro metabolism studies with zatosetron proved to be useful in the design of both toxicological and clinical studies. With regard to the toxicological studies, zatosetron N-oxide was found to be the major human metabolite formed in vivo and in vitro. In vivo and/or in vitro studies demonstrated that the rat, mouse, and dog did not produce a substantial amount of this metabolite, indicating that these species would not be exposed to zatosetron N-oxide at levels approaching those of the human volunteers. However, the in vitro studies with hepatic microsomes from the rhesus monkey indicate that zatosetron N-oxide would be produced as the major metabolite of zatosetron in vivo. Therefore, the rhesus monkey appears to be better than rat, mouse, or dog as an animal model for the human exposure to zatosetron and zatosetron N-oxide.
The finding that human CYP3A is responsible for the formation of the major metabolite of zatosetron can be used to guide the clinical studies in the development of zatosetron. First, it should be noted that only 60% of a dose of zatosetron is excreted as metabolites. Therefore, a large variation in CYP3Amediated zatosetron metabolism would be required before a clinically significant effect would be noted. For example, the nearly complete inhibition of CYP3A by agents that complex or inactivate CYP3A (like ketoconazole) would be predicted to decrease the clearance of zatosetron. Furthermore, concomitant chronic administration of high-affinity substrates of CYP3A like cyclosporin CKrn --3 Am) would be predicted to decrease the metabolism of zatosetron. Potent inducers of CYP3A like rifampicin would be predicted to increase the metabolism of zatosetron. However, because zatosetron is a lowaffinity substrate for CYP3A (K&dquo;, ~ 250 Am), it would be expected to have little effect on the metabolic clearance of most CYP3A substrates. If additional in vitro drug--drug interaction studies with formselective substrates of the other P-450s indicate that zatosetron has little affinity for these other P-450s, the need for in vivo interaction studies between zatosetron and clinically used substrates of these P-450s would appear not to be warranted.
